MX2022003002A - Secuencia de extension n-terminal para la expresion de peptidos terapeuticos recombinantes. - Google Patents

Secuencia de extension n-terminal para la expresion de peptidos terapeuticos recombinantes.

Info

Publication number
MX2022003002A
MX2022003002A MX2022003002A MX2022003002A MX2022003002A MX 2022003002 A MX2022003002 A MX 2022003002A MX 2022003002 A MX2022003002 A MX 2022003002A MX 2022003002 A MX2022003002 A MX 2022003002A MX 2022003002 A MX2022003002 A MX 2022003002A
Authority
MX
Mexico
Prior art keywords
expression
terminal extension
therapeutic peptides
recombinant therapeutic
extension sequence
Prior art date
Application number
MX2022003002A
Other languages
English (en)
Inventor
Ramesh Venkat Matur
Narender Dev Mantena
Mahima Datla
Rajan Sriraman
Pavan Reddy Regatti
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of MX2022003002A publication Critical patent/MX2022003002A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se relaciona con secuencias de extensión N-terminal las cuales se emplean para mejorar la expresión de péptidos terapéuticos recombinantes. La invención también se relaciona con un proceso para la expresión de alto nivel de péptidos terapéuticos recombinantes usando la secuencia de extensión N-terminal. La invención también proporciona ácidos nucleicos, vectores y células anfitrionas recombinantes para la producción eficiente de proteínas biológicamente activas como lirapéptido.
MX2022003002A 2019-09-13 2020-09-12 Secuencia de extension n-terminal para la expresion de peptidos terapeuticos recombinantes. MX2022003002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941009728 2019-09-13
PCT/IN2020/050790 WO2021048878A1 (en) 2019-09-13 2020-09-12 N-terminal extension sequence for expression of recombinant therapeutic peptides

Publications (1)

Publication Number Publication Date
MX2022003002A true MX2022003002A (es) 2022-04-07

Family

ID=74866188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003002A MX2022003002A (es) 2019-09-13 2020-09-12 Secuencia de extension n-terminal para la expresion de peptidos terapeuticos recombinantes.

Country Status (14)

Country Link
US (1) US20230002468A1 (es)
EP (1) EP4028519A4 (es)
JP (1) JP2022548598A (es)
KR (1) KR20220058631A (es)
CN (1) CN114651063A (es)
AU (1) AU2020345138A1 (es)
BR (1) BR112022004601A2 (es)
CA (1) CA3150902A1 (es)
CO (1) CO2022004535A2 (es)
CU (1) CU20220017A7 (es)
IL (1) IL291127A (es)
MX (1) MX2022003002A (es)
WO (1) WO2021048878A1 (es)
ZA (1) ZA202202579B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4314034A2 (en) * 2021-03-31 2024-02-07 Biological E Limited Constructs and methods for increased expression of polypeptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082671A1 (en) * 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
CA2865578C (en) * 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
US20190352365A1 (en) * 2017-01-18 2019-11-21 Savior Lifetec Corporation Expression construct and method for producing proteins of interest
WO2019082138A1 (en) * 2017-10-27 2019-05-02 Lorven Biologics Private Limited PROCESS FOR THE PREPARATION OF LIRAGLUTIDE USING RECOMBINANT SACCHAROMYCES CEREVISIAE
CN107881187A (zh) * 2017-11-20 2018-04-06 珠海联邦制药股份有限公司 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
CN108218997B (zh) * 2017-12-30 2020-12-15 北京中科唯新生物医学研究所有限公司 一种用于纯化蛋白的表达载体
JP2021511785A (ja) * 2018-01-19 2021-05-13 ペプジーン インコーポレーテッドＰｅｐｇｅｎｅ Ｉｎｃ． 組換えポリペプチド生産用ｎ末端融合パートナーおよびこれを用いた組換えポリペプチドの生産方法

Also Published As

Publication number Publication date
KR20220058631A (ko) 2022-05-09
US20230002468A1 (en) 2023-01-05
CO2022004535A2 (es) 2022-04-29
EP4028519A1 (en) 2022-07-20
ZA202202579B (en) 2022-10-26
AU2020345138A1 (en) 2022-04-21
WO2021048878A1 (en) 2021-03-18
EP4028519A4 (en) 2023-10-11
BR112022004601A2 (pt) 2022-05-31
IL291127A (en) 2022-05-01
JP2022548598A (ja) 2022-11-21
CU20220017A7 (es) 2022-10-11
CA3150902A1 (en) 2021-03-18
CN114651063A (zh) 2022-06-21

Similar Documents

Publication Publication Date Title
AU2018298422A1 (en) Novel nucleic acid molecules
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
UA120917C2 (uk) Химерний білок фактора viii та його застосування
PH12018501628A1 (en) Optimized factor viii genes
MX2021003261A (es) Neurotoxinas clostridiales que comprenden un bucle de activacion exogeno.
WO2005033316A3 (de) Sekretion von proteinen aus hefen
PH12020551134A1 (en) Fc variants with enhanced binding to fcrn and prolonged half-life
JP2018528237A5 (es)
NZ596735A (en) Recombinant production of peptides
NZ705575A (en) Recombinant clostridium botulinum neurotoxins
MX2018010850A (es) Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
WO2016130628A8 (en) Griffithsin mutants
MX2019003360A (es) Vectores de expresion para una secrecion de proteina mejorada.
NZ724196A (en) Uti fusion proteins
MX2022006385A (es) Acidos nucleicos, vectores, celulas huespedes y metodos para la produccion de beta-fructofuranosidasa a partir de aspergillus niger.
MX2022004345A (es) Construcciones de igf2 variantes.
MX2010009071A (es) Peptidos aislados que tienen actividad inhibitoria de fosfolipasa.
MX2022003002A (es) Secuencia de extension n-terminal para la expresion de peptidos terapeuticos recombinantes.
WO2018132821A3 (en) Elastomeric proteins
PH12020551357A1 (en) Expression of pneumococcal surface protein a (pspa)
ZA202308985B (en) Constructs and methods for increased expression of polypeptides
SG11201902998SA (en) PROMOTER OF Hspa5 GENE
MX2018003445A (es) Expresion de proteinas que contienen fc.
WO2019046446A3 (en) COMPOSITIONS AND METHODS USING METHANOTROPHE LAYER PROTEINS FOR THE EXPRESSION OF HETEROLOGOUS PROTEINS